Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interleukin-2 antitumor and effector cell responses

M J Hawkins1

  • 1Lombardi Cancer Research Center, Washington, DC 20007.

Seminars in Oncology
|December 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Employee stress claims: increasing implications for health promotion programming.

American journal of health promotion : AJHP·2011
Same author

Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2006
Same author

Placebo-controlled trial of bexarotene, a retinoid x receptor agonist, as maintenance therapy for patients treated with chemotherapy for advanced non-small-cell lung cancer.

Clinical lung cancer·2004
Same author

A phase I and pharmacokinetic study of squalamine, a novel antiangiogenic agent, in patients with advanced cancers.

Clinical cancer research : an official journal of the American Association for Cancer Research·2001
Same author

Phase I and pharmacokinetic study of two sequences of gemcitabine and docetaxel administered weekly to patients with advanced cancer.

Cancer chemotherapy and pharmacology·2001
Same author

Final analysis of the ECOG I-COPA trial (E6484) in patients with non-Hodgkin's lymphoma treated with interferon alfa (IFN-alpha2a) plus an anthracycline-based induction regimen.

Leukemia·2001
Same journal

A systematic scoping review of cancer-related anemia treatment: Comparative trial outcomes, current guidelines, and future perspectives.

Seminars in oncology·2026
Same journal

Steroid-induced tumor lysis syndrome in solid tumors: A case report and review of the literature.

Seminars in oncology·2026
Same journal

PSMA PET/CT staging in intermediate-risk prostate cancer: Toward risk-adapted implementation.

Seminars in oncology·2026
Same journal

Angiogenesis and the corresponding antiangiogenic therapy in gastroenteropancreatic neuroendocrine neoplasms.

Seminars in oncology·2026
Same journal

Post-translational regulation of steroidogenesis and its clinical relevance in hormone responsive cancers.

Seminars in oncology·2026
Same journal

Physics-informed machine learning for tumor microenvironment-responsive nanomedicine: Recent updates.

Seminars in oncology·2026
See all related articles

Recombinant interleukin-2 (rIL-2) efficacy depends on the effector cell. Lymphokine-activated killer (LAK) cells require high rIL-2 doses for non-immunogenic tumors, while cytotoxic T-lymphocytes (CTLs) may target advanced cancers, including renal cell carcinoma (RCC).

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • Recombinant interleukin-2 (rIL-2) has shown antitumor effects, but its clinical development is influenced by the specific immune effector cells involved.
  • Understanding the role of different effector cells, such as lymphokine-activated killer (LAK) cells and cytotoxic T-lymphocytes (CTLs), is crucial for optimizing rIL-2 therapy.

Purpose of the Study:

  • To explore the implications of different effector cells (LAK vs. CTL) on the clinical development and treatment strategies for rIL-2.
  • To analyze the conditions under which LAK cell-mediated and CTL-mediated antitumor effects are most effective.

Main Methods:

  • The study is based on preclinical models and clinical observations of rIL-2 activity.
  • It involves analyzing the relationship between rIL-2 dose, tumor burden, tumor immunogenicity, and effector cell populations (LAK and CTL).

Related Experiment Videos

Main Results:

  • LAK cell-mediated antitumor effects likely necessitate high rIL-2 doses and are most effective against non-immunogenic tumors in low tumor burden states.
  • CTL-mediated killing may be effective against weakly immunogenic tumors, even in advanced stages, as suggested by rIL-2 activity in some renal cell carcinoma (RCC) patients.
  • Generating relevant effector cell populations is predicted to enhance CTL-dependent rIL-2 antitumor activity.

Conclusions:

  • Clinical development of rIL-2 should consider the specific effector cell type driving antitumor responses.
  • Treatment strategies may need to be tailored based on tumor characteristics (immunogenicity, burden) and the desired effector cell activation.
  • Enhancing CTL responses, potentially through multiple tumor antigen-specific T-cell populations, could lead to more complete and durable antitumor activity, especially in heterogeneous tumors.